CVE:KNEKane Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kane Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.14 0.00 (-3.45 %) (As of 06/4/2020 01:57 PM ET) Add Compare Share Today's RangeC$0.12Now: C$0.14▼C$0.1450-Day RangeC$0.12MA: C$0.14▼C$0.1552-Week RangeC$0.09Now: C$0.14▼C$0.26Volume20,000 shsAverage Volume79,361 shsMarket CapitalizationC$15.21 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Kane Biotech. Previous Next 2.1 Community Rank Outperform VotesKane Biotech has received 52 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKane Biotech has received 72 “underperform” votes. (Add your “underperform” vote.)Community SentimentKane Biotech has received 58.06% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kane Biotech and other stocks. Vote “Outperform” if you believe KNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KNE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKane Biotech does not currently pay a dividend.Dividend GrowthKane Biotech does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kane Biotech insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Kane Biotech is -11.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kane Biotech is -11.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKane Biotech has a P/B Ratio of 17.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.42 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:KNE Previous Symbol CUSIPN/A CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301Debt Debt-to-Equity Ratio25.29 Current Ratio1.42 Quick Ratio0.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$1.69 million Price / Sales8.98 Cash FlowC$0.01 per share Price / Cash Flow17.50 Book ValueC$0.01 per share Price / Book17.50Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares108,614,000Market CapC$15.21 million Next Earnings Date8/19/2020 (Estimated) OptionableNot Optionable TSXV:KNE Rates by TradingView Receive KNE News and Ratings via Email Sign-up to receive the latest news and ratings for KNE and its competitors with MarketBeat's FREE daily newsletter. Kane Biotech (CVE:KNE) Frequently Asked Questions How has Kane Biotech's stock been impacted by COVID-19 (Coronavirus)? Kane Biotech's stock was trading at C$0.18 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KNE stock has decreased by 22.2% and is now trading at C$0.14. View which stocks have been most impacted by Coronavirus. When is Kane Biotech's next earnings date? Kane Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for Kane Biotech. How were Kane Biotech's earnings last quarter? Kane Biotech Inc (CVE:KNE) posted its earnings results on Thursday, April, 2nd. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $0.56 million during the quarter. View Kane Biotech's earnings history. Has Kane Biotech been receiving favorable news coverage? Press coverage about KNE stock has been trending somewhat negative on Thursday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kane Biotech earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutKane Biotech. Who are some of Kane Biotech's key competitors? Some companies that are related to Kane Biotech include e-Therapeutics (ETX), Promis Neurosciences (PMN), Emerald Health Therapeutics (EMH), Navidea Biopharmaceuticals (NAVB), Medlab Clinical (MDC), OptiBiotix Health (OPTI), Cocrystal Pharma (COCP), Protalix Biotherapeutics (PLX), Verona Pharma (VRP), Memphasys (MEM), Zelda Therapeutics (ZLD), ReNeuron Group (RENE), Botanix Pharmaceuticals (BOT), Covalon Technologies (COV) and Race Oncology (RAC). View all competitors. Who are Kane Biotech's key executives? Kane Biotech's management team includes the following people: Mr. Marc Edwards, Interim CEO & DirectorMr. Ray Dupuis, Chief Financial OfficerMr. Mark Ahrens-Townsend, AdvisorDr. Gordon Guay, Chief Scientific Officer & Member of Scientific Advisory BoardMr. L. Michael Coutts, Director of Bus. Devel. What is Kane Biotech's stock symbol? Kane Biotech trades on the Canadian Venture Exchange (CVE) under the ticker symbol "KNE." How do I buy shares of Kane Biotech? Shares of KNE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Kane Biotech's stock price today? One share of KNE stock can currently be purchased for approximately C$0.14. How big of a company is Kane Biotech? Kane Biotech has a market capitalization of C$15.21 million and generates C$1.69 million in revenue each year. What is Kane Biotech's official website? The official website for Kane Biotech is www.kanebiotech.com. How can I contact Kane Biotech? Kane Biotech's mailing address is 162-196 Innovation Dr, WINNIPEG, MB R3T 6C5, Canada. The company can be reached via phone at +1-204-4531301. This page was last updated on 6/4/2020 by MarketBeat.com Staff
